目的 探討小建中膠囊聯(lián)合拉呋替丁治療胃潰瘍的臨床研究。方法 選取2019年6月—2021年6月在天津市北辰醫(yī)院中醫(yī)科診治的126例胃潰瘍患者，隨機分為對照組和治療組，每組各63例。對照組餐后口服拉呋替丁片，10 mg/次，2次/d。治療組在對照組基礎(chǔ)上口服小建中膠囊，3粒/次，3次/d。兩組患者連續(xù)用藥7 d。觀察兩組患者臨床療效，比較治療前后兩組臨床癥狀緩解時間，胃動素（MTL）、胃泌素（GAS）和膽囊收縮素（CCK）水平，血清白細胞介素-6（IL-6）、白細胞介素-1β（IL-1β）、腫瘤壞死因子-α（TNF-α）和C反應(yīng)蛋白（CRP）水平，及不良反應(yīng)情況。結(jié)果 治療后，治療組患者臨床總有效率明顯高于對照組（98.41%vs 84.13%，P<0.05）。治療后，治療組患者臨床癥狀緩解時間明顯短于對照組（P<0.05）。治療后，兩組患者MTL水平明顯升高，而GAS和CCK水平明顯下降（P<0.05），且治療組MTL、GAS和CCK水平明顯好于對照組（P<0.05）。治療后，兩組患者血清IL-6、TNF-α和CRP水平明顯降低，而IL-1β水平明顯升高（P<0.05），且治療組患者血清水平明顯好于對照組（P<0.05）。治療期間，治療組藥物不良反應(yīng)發(fā)生率明顯低于對照組（4.76%vs 11.21%，P<0.05）。結(jié)論 小建中膠囊聯(lián)合拉呋替丁治療胃潰瘍療效顯著，可有效緩解臨床癥狀，并能降低炎癥反應(yīng)，加快潰瘍面愈合，具有一定臨床推廣應(yīng)用價值。

Objective To explore the clinical study of Xiaojianzhong Capsules combined with lafutidine in treatment of gastric ulcer. Methods Patients (126 cases) with gastric ulcer in Tianjin Beichen Hospital from June 2019 to June 2021 were randomly divided into control and treatment group, and each group had 63 cases. Patients in the control group were po administered with Lafutidine Tablets after meals, 10 mg/time, twice daily. Patients in the treatment group were po administered with Xiaojianzhong Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 7 d. After treatment, the clinical evaluation was evaluated, the improvement time of clinical symptoms, the levels of MTL, GAS and CCK, the levels of IL-1β, IL-6, TNF-α and CRP, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the total clinical effective rate in the treatment group was significantly higher than that in the control group (98.41% vs 84.13%, P< 0.05). After treatment, the relief time of clinical symptoms in the treatment group was significantly lower than that in the control group (P< 0.05). After treatment, the level of MTL in two groups were significantly increased, while the levels of GAS and CCK were significantly decreased (P < 0.05), and the levels of MTL, GAS and CCK in the treatment group were significantly better than those in the control group (P < 0.05). After treatment, the serum levels of IL-6, TNF-α and CRP in two groups were significantly decreased, while the level of IL-1β were significantly increased, and the serum level in the treatment group was significantly better than that in the control group (P < 0.05). During the treatment, the incidence of adverse drug reactions in the treatment group was significantly lower than that in the control group (4.76% vs 11.21%, P < 0.05). Conclusion Xiaojianzhong Capsules combined with lafutidine in treatment of gastric ulcer has a significant effect, can effectively relieve clinical symptoms, reduce inflammatory reaction and speed up ulcer healing, which has a certain clinical application value.

R975

天津市衛(wèi)生和計劃生育委員會中醫(yī)中西醫(yī)結(jié)合科研課題（2017052）